Home / Health / Diabetes Drug Shows Promise for Addiction Treatment
Diabetes Drug Shows Promise for Addiction Treatment
20 Sep
Summary
- GLP-1 drugs, initially for diabetes, may help treat addiction.
- Studies show these drugs reduce cravings for alcohol and other substances.
- Experts caution that more research is needed before wider use.
Researchers are exploring the potential of GLP-1 drugs, such as Ozempic and Mounjaro, to treat addiction. Initially developed for diabetes, these medications have gained popularity for weight loss due to their effects on appetite and cravings. Scientists are now investigating if these properties can be repurposed to combat drug and alcohol dependency.
A study published in The Lancet indicated that GLP-1 receptor agonists significantly reduced heavy drinking days in individuals with obesity and alcohol use disorder. This effect is thought to be similar to how they suppress appetite, providing a 'stop button' for cravings.
Further observational data from US veterans suggests that GLP-1 receptor agonists may reduce the risk of developing new substance use disorders, including those involving alcohol, cannabis, and opioids. They were also associated with fewer adverse outcomes like hospitalizations and mortality in those with pre-existing addictions.
However, experts caution that this research is still in its early stages. Concerns exist about potential weight regain and a rebound in addictive behaviors after stopping the medication. The long-term effects and efficacy compared to existing treatments are yet to be fully understood, with conclusive results anticipated in five to ten years.
